Bvf Inc Cytom X Therapeutics, Inc. Transaction History
Bvf Inc
- $3.27 Billion
- Q2 2024
A detailed history of Bvf Inc transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Bvf Inc holds 5,228,461 shares of CTMX stock, worth $5.23 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
5,228,461
Previous 6,595,801
20.73%
Holding current value
$5.23 Million
Previous $14.4 Million
55.64%
% of portfolio
0.2%
Previous 0.43%
Shares
15 transactions
Others Institutions Holding CTMX
# of Institutions
75Shares Held
50.4MCall Options Held
22.3KPut Options Held
22.9K-
Tang Capital Management LLC San Diego, CA7.79MShares$7.79 Million1.16% of portfolio
-
Janus Henderson Group PLC London, X06.3MShares$6.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$4.89 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$3 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA2.73MShares$2.73 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $66M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...